“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin has been a global leader in the Anti-TB APIs for several years. This has enabled it to forward integrate its API strengths and launch Fixed Dose Combinations (FDCs) to supply to various Government agencies, National TB program, the Stop TB Partnership and various other international agencies. Lupin has, over the years, proved its capabilities in sterile manufacturing, synthetic process development, fermentation, managing complex chemistries and expertise in enzymatic biotransformation. Lupin's strengths in Process Research and management of Intellectual Property provide it the skill-sets critical to master any complex process or product. The Company's capabilities in backward integration, empower it to approach the market with a wide spectrum of products at competitive prices. Its skill in manufacturing products, benchmarked to the best international standards, is evidenced by the fact that nine of its API plants have secured US FDA approval and two plants have secured UK MHRA approval.
Lupin is pre-qualified as a preferred supplier to the Global Drug Facility (GDF). These formulations are being supplied to more than 50 countries through GDF procurement. The Company also supplies to various international institutions like Pan America Health Organisation (PAHO), Medicines Sans Frontier (MSF) and the Damien Foundation. Today, Multi Drug Resistance (MDR TB) and Extensively Drug Resistance TB (XDR TB) are emerging as major threats for the population of high TB burden countries in Asia, Africa and Latin America. Funding from newer sources is pouring in for the treatment of MDR TB and Paediatric TB. The Company is looking at expanding its spectrum of offerings in the Anti-TB range to include APIs in the MDR TB category. The twin area of MDR TB and Paediatric TB provides additional opportunity for Lupin to strengthen its global leadership and become one-stop-shop for the global TB solutions. The Company is also associated with the Revised National TB Program of the Government of India, thereby partnering the Government in its fight against TB in the country.